Literature DB >> 8074075

Correlation between long-chain acylcarnitine in serum and myocardium after heart transplantation in humans.

H G Olbrich1, A Evangeliou, S B Tabatabaei, G Cieslinski, A Hartmann, F Beyersdorf, G Hermann, H Böhles.   

Abstract

The concentrations of free, short-chain, and long-chain acylcarnitine were determined in 19 right ventricular endomyocardial biopsies and in serum from 14 patients after orthotopic heart transplantation and 3 nontransplanted control patients with normal cardiac function. Coronary angiography was normal in all patients. Left ventricular ejection fraction as measured by radionuclide ventriculography was not different between heart-transplanted and control patients (60.3 +/- 6.7% and 61.7 +/- 10.7%, respectively). Myocardial and serum carnitine concentrations in heart-transplanted patients were not different from control patients (myocardium: free carnitine 11.8 +/- 4.8 vs 7.1 +/- 7.1, short-chain acylcarnitine 4.5 +/- 2.1 vs 5.8 +/- 2.0, long-chain acylcarnitine 4.9 +/- 3.8 vs 3.9 +/- 3.2 mumol/g noncollagen protein; serum: free carnitine 32.6 +/- 11.2 vs 32.0 +/- 9.9, short-chain acylcarnitine 7.3 +/- 5.2 vs 5.1 +/- 1.3, long-chain acylcarnitine 4.1 +/- 2.7 vs 4.8 +/- 4.0 mumol/L). There was a highly significant correlation between myocardial and serum long-chain acylcarnitine (r = 0.76, P < 0.001). The data suggest that carnitine metabolism is not altered after heart transplantation.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8074075     DOI: 10.1093/ajcn/60.3.414

Source DB:  PubMed          Journal:  Am J Clin Nutr        ISSN: 0002-9165            Impact factor:   7.045


  3 in total

1.  Acylcarnitines are anticoagulants that inhibit factor Xa and are reduced in venous thrombosis, based on metabolomics data.

Authors:  Hiroshi Deguchi; Yajnavalka Banerjee; Sunia Trauger; Gary Siuzdak; Ewa Kalisiak; José A Fernández; Linh Hoang; Minerva Tran; Subramanian Yegneswaran; Darlene J Elias; John H Griffin
Journal:  Blood       Date:  2015-07-14       Impact factor: 22.113

Review 2.  Acylcarnitines in intermediary metabolism.

Authors:  A C Sewell; H J Böhles
Journal:  Eur J Pediatr       Date:  1995-11       Impact factor: 3.183

3.  Minor Plasma Lipids Modulate Clotting Factor Activities and May Affect Thrombosis Risk.

Authors:  Hiroshi Deguchi; Darlene J Elias; John H Griffin
Journal:  Res Pract Thromb Haemost       Date:  2017-06-20
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.